TrialBreast cancer research and treatment2021

Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.

Matthew Kearney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.